Cited by 475SARS-CoV-2 and COVID-19 ResearchPharmacovigilance and Adverse Drug ReactionsFood Allergy and Anaphylaxis Research

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021

Open access

Shimabukuro, Tom T., Cole, Matthew, Su, John R.·2021·JAMA

DOI 10.1001/jama.2021.1967PMC PMC8890485

Open this paper in CoChat — free account Open PDF

Abstract

This JAMA Insights review provides clinical details of anaphylactic reactions reported to and verified by the CDC in the first month of use of the Pfizer-BioNTech and Moderna COVID-19 vaccines in the US, December 14, 2020-January 18, 2021.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jama.2021.1967

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)
Shimabukuro, T. T., Nguyen, M., Martin, D., & Destefano, F. R. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.07.035 · Cited by 627
Self-citation
The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020
Oliver, S. E., Gargano, J. W., Marin, M., Wallace, M. M., Curran, K. G., Chamberland, M. E., McClung, N. M., Campos-Outcalt, D. E., Morgan, R. L., Mbaeyi, S. A., et al. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6950e2 · Cited by 536
Anaphylaxis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data
Rüggeberg, J. U., Gold, M., Bayas, J. M., Blum, M. D., Bonhoeffer, J., Friedlander, S. F., Brito, G. D. S., Heininger, U., Imoukhuede, E. B., Khamesipour, A., et al. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.02.064 · Cited by 383
Excess Deaths Associated with COVID-19, by Age and Race and Ethnicity — United States, January 26–October 3, 2020
Rossen, L. M., Branum, A. M., Ahmad, F. B., Sutton, P., & Anderson, R. N. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6942e2 · Cited by 373
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine
Shimabukuro, T. T., & Nair, N. (2021) · JAMA · doi:10.1001/jama.2021.0600 · Cited by 327
Self-citation
The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020
Oliver, S. E., Gargano, J. W., Marin, M., Wallace, M. M., Curran, K. G., Chamberland, M. E., McClung, N. M., Campos-Outcalt, D. E., Morgan, R. L., Mbaeyi, S. A., et al. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm695152e1 · Cited by 317
Vaccine-associated hypersensitivity
McNeil, M. M., & Destefano, F. R. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.12.971 · Cited by 274
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine — United States, December 21, 2020–January 10, 2021
CDC COVID-19 Response Team, & Administration, F. A. D. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7004e1 · Cited by 270

Show all 8 references

Sorted by citations

Items 201–300 of 474

Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective
Blakney, A. K., Top, K. A., Cowling, B. J., Larson, H. J., Shattock, R. J., & Sadarangani, M. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00512-x · Cited by 11
Risk Factors for Grade 3 to Grade 4 Adverse Reactions to the ChAdOx1 nCoV-19 Vaccine (AZD1222) Against SARS-CoV-2
Lee, S. W., Lee, H. J., Lee, S.-K., Moon, J., Moon, S., Chung, S. J., Yeo, Y., Park, T. S., Park, D. W., Kim, T., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.738049 · Cited by 8
Revaccination outcomes among adolescents and adults with suspected hypersensitivity reactions following COVID-19 vaccination: A Canadian immunization research network study
Fitzpatrick, T., Yamoah, P., Lacuesta, G., Sadarangani, M., Cook, V. E., Pourshahnazari, P., Kalicinsky, C., Upton, J. E. M., Cameron, S. B., Zaborniak, K., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.06.045 · Cited by 8
Specialist confirmed allergic reactions to COVID-19 mRNA vaccines at a mass vaccination site
Myles, I. A., Vinciguerra, J. S., & Premus, R. T. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.06.061 · Cited by 8
Safety of BNT162b2 mRNA COVID-19 vaccine in patients with mast cell disorders
Rosman, Y., Lavi, N., Meir‐Shafrir, K., Lachover‐Roth, I., Cohen‐Engler, A., Mekori, Y. A., & Confino‐Cohen, R. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.06.032 · Cited by 8
Delayed angioedema after administration of the severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine
Watts, M. M., Maurer, L. E., Grammer, L. C., Saltoun, C. A., & Stevens, W. W. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.10.021 · Cited by 8
Attention for sex in COVID-19 trials: a review of regulatory dossiers
de Vries, S. T., Starokozhko, V., Schellens, I. M. M., Wijnans, L., Enzmann, H. G., Cavaleri, M., & Mol, P. G. M. (2022) · BMJ Global Health · doi:10.1136/bmjgh-2021-008173 · Cited by 8
Ocular Inflammatory Reactions following an Inactivated SARS-CoV-2 Vaccine: A Four Case Series
JunHong, R., Zhang, T., Li, X., & Liu, G. (2022) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2022.2093754 · Cited by 8
Vaccine confidence among those living with allergy during the COVID pandemic (ACCORD): A scoping review
Batac, A. L. R., Merrill, K. A., Askin, N., Golding, M. A., Abrams, E. M., Bégin, P., Ben‐Shoshan, M., Ladouceur, E., Roos, L. E., Protudjer, V., et al. (2023) · Journal of Allergy and Clinical Immunology Global · doi:10.1016/j.jacig.2023.100079 · Cited by 8
Allergic Reactions to Vaccines in Children: From Constituents to Specific Vaccines
Tsai, M., & Chiu, C. (2023) · Biomedicines · doi:10.3390/biomedicines11020620 · Cited by 8
COVID-19, Law & Regulation
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · doi:10.1093/oso/9780192896742.001.0001 · Cited by 9
Updated Considerations for the Immunopharmacological Aspects of the “Talented mRNA Vaccines”
Perrotta, C., Fenizia, C., Carnovale, C., Pozzi, M., Trabattoni, D., Cervia, D., & Clementi, E. (2023) · Vaccines · doi:10.3390/vaccines11091481 · Cited by 9
Female-Male Differences in COVID Vaccine Adverse Events Have Precedence in Seasonal Flu Shots: A Potential Link to Sex-Associated Baseline Gene Expression PatternsPreprint
Venkatakrishnan, A., Kumar, P. M., Silvert, E., Garcia-Rivera, E., Szenk, M., Suratekar, R., Lenehan, P. J., Lindemer, E., O’Horo, J. C., Williams, A. W., et al. (2021) · SSRN Electronic Journal · doi:10.1101/2021.04.01.21254798 · Cited by 8
mRNA COVID-19 Vaccine–Related Anaphylactoid Reaction and Coronary Thrombosis
Hinton, J., Gala, A. R. P. B. E., & Corbett, S. J. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.10.010 · Cited by 7
Polyethylene glycol hypersensitivity, patient outcomes in a 7-year retrospective study
Kayode, O. S., Nakonechna, A., Siew, L. Q. C., Dziadzio, M., Kennard, L., Rutkowski, K., Mirakian, R. M., & Wagner, A. (2024) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2024.03.022 · Cited by 7
COVID-19 mRNA-1273 vaccination induced mast cell activation with strongly elevated Th2 cytokines in a systemic mastocytosis patient
Weiss-Tessbach, M., Haider, T., Gowran, A., Schubert, L., Mühlbacher, J., Brankovic, J., Wahrmann, M., Jilma, B., & Boehm, T. (2025) · Inflammation Research · doi:10.1007/s00011-025-02032-5 · Cited by 7
Safety Monitoring of Bivalent COVID ‐19 mRNA Vaccines Among Recipients 6 Months and Older in the United States
Lloyd, P. C., Smith, E. R., Gruber, J. F., Ondari, M., Wong, H., Hu, M., Clarke, T. C., McEvoy, R., Amend, K. L., Beachler, D. C., et al. (2025) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70151 · Cited by 7
An academic hospital experience screening mRNA COVID-19 vaccine risk using patient allergy history
Krantz, M. S., Stone, C. A., Rolando, L. A., Nobis, A., Koo, G., Corey, K. B., Bluestein, S., Staso, P. J., Campbell, E. M., & Phillips, E. J. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.07.010 · Cited by 7
COVAX no fault compensation program for COVID-19 vaccine injuries in 92 low and middle income countries
Mazur, A., McMonagle, S. B., Chuffart-Finsterwald, S., Rotta, R. L., & Hampton, L. M. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.10.047 · Cited by 7
Comparative assessment of allergic reactions to COVID‐19 vaccines in Europe and the United States
Hatziantoniou, S., Anastassopoulou, C. G., Lampropoulou, V., Maltezou, H. C., Andreakos, E., Poland, G. A., & Tsakris, A. (2022) · Allergy · doi:10.1111/all.15257 · Cited by 7
A case of coronavirus disease 2019 messenger RNA vaccine tolerance and immune response despite presence of anti-polyethylene glycol antibodies
Corey, K. B., Koo, G., Stone, C. A., Kroop, S. F., Fissell, W. H., Kozlowski, S., Zhou, Z., & Phillips, E. J. (2022) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2022.05.013 · Cited by 7
Acute Severe Ulcerative Colitis After mRNA Coronavirus Disease 2019 Vaccination: Can mRNA Vaccines Unmask Inflammatory Bowel Diseases?
Ak, Ç., Sayar, S., Adalı, G., & Özdil, K. (2022) · ACG Case Reports Journal · doi:10.14309/crj.0000000000000806 · Cited by 7
Adverse events of the Pfizer-BioNTech COVID-19 vaccine in Korean children and adolescents aged 5 to 17 years
Kim, S., Heo, Y., Seo, S.-Y., Lim, D. S., Cho, E., & Lee, Y.-K. (2022) · Osong Public Health and Research Perspectives · doi:10.24171/j.phrp.2022.0233 · Cited by 7
COVID-19 Vaccines—All You Want to Know
Shishido, A. A., Barnes, A. H., Narayanan, S., & Chua, J. V. (2023) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0042-1759779 · Cited by 6
Identifying and Managing Those at Risk for Vaccine-Related Allergy and Anaphylaxis
Stone, C. A., Garvey, L. H., Nasser, S. M., Lever, C., Triggiani, M., Parente, R., & Phillips, E. J. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.05.004 · Cited by 8
The Importance of a Timely Second Dose of the 2021 COVID-19 mRNA Vaccine Depends on the Protection Afforded by a First Dose and Subsequent Risk of Anaphylaxis
Shaker, M. S., Phillips, E. J., Blumenthal, K. G., Abrams, E. M., Banerji, A., Oppenheimer, J. J., Leek, T. K. V., Mack, D. P., Wickner, P. G., Singer, A. G., et al. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.04.015 · Cited by 7
Biphasic anaphylaxis after first dose of messenger RNA coronavirus disease 2019 vaccine with positive polysorbate 80 skin testing result
Pitlick, M. M., Park, M. A., Gonzalez‐Estrada, A., & Chiarella, S. E. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.07.020 · Cited by 7
Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
Goh, Y. S., Fong, S., Rouers, A., Chang, Z. W., Tay, M. Z., Chavatte, J., Zhuo, N. Z., Hor, P. X., Loh, C. Y., Huang, Y., et al. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1403 · Cited by 7
The Application of mRNA Technology for Vaccine Production—Current State of Knowledge
Paczkowska, A., Hoffmann, K., Andrzejczak, A., Pucek, W. F., Kopciuch, D., Bryl, W., Nowakowska, E., & Kus, K. (2025) · Vaccines · doi:10.3390/vaccines13040389 · Cited by 9
Engineering Lipid Nanoparticles for Precision RNA Delivery: Design Principles, Targeting Strategies, and Clinical Prospects
Han, Y., Wang, Y., Gao, X., Lei, Y., Li, Y., & Tang, Z. (2026) · Cancer Nexus · doi:10.1002/cnx2.70021 · Cited by 8
The cost-effectiveness of vaccination against COVID-19 illness during the initial year of vaccination
Prosser, L. A., Perroud, J., Chung, G. S., Gebremariam, A., Janusz, C. B., Mercon, K. R., Rose, A. M., Avanceña, A. L. V., DeLuca, E. K., & Hutton, D. W. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126725 · Cited by 6
COVID-19: The Vaccine Race Continues
Burgess, L. H., Castelein, C., Rubio, A. G., & Cooper, M. K. (2021) · HCA Healthcare Journal of Medicine · doi:10.36518/2689-0216.1269 · Cited by 5
Allergic Reactions After COVID-19 Vaccination—Putting Risk Into Perspective
Phillips, E. J. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.22326 · Cited by 6
Allergic reactions to the Ad26.COV2.S vaccine in South Africa
Peter, J., Day, C., Takuva, S. G., Takalani, A., Engelbrecht, I., Garrett, N., Goga, A. E., Louw, V. J., Opie, J., Jacobson, B. F., et al. (2021) · Journal of Allergy and Clinical Immunology Global · doi:10.1016/j.jacig.2021.12.002 · Cited by 6
AstraZeneca ChAdOx1-S COVID-19 vaccine can be safely administered in patients with EDTA allergy
Ali, S. B., Perkins, G. B., Ryoo, D., Lee, M., Tunbridge, M. J., Yuson, C., Smith, W., Hissaria, P., & Le, T. A. (2022) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-022-00665-3 · Cited by 6
Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?
He, X., & Zeng, X. X. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s347297 · Cited by 7
Successful mRNA COVID-19 Vaccination and Colonoscopy After Oral Desensitization in a Patient With Polyethylene Glycol Allergy
Cha, B., Kwon, K. S., Lee, H. L., & Kim, C.-W. (2022) · Journal of Korean Medical Science · doi:10.3346/jkms.2022.37.e251 · Cited by 6
Anaphylaxis after COVID-19 vaccination: A registry-based study
Jaggers, J. L., Samarakoon, U., Fu, X., Gonzalez‐Estrada, A., Anvari, S., Chong, H., Meerbeke, S. W. V., Petrov, A. A., Chow, T. G., Banerji, A., et al. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.08.008 · Cited by 6
Mining adverse events in large frequency tables with ontology, with an application to the vaccine adverse event reporting system
Zhao, B., & Zhao, L. (2023) · Statistics in Medicine · doi:10.1002/sim.9684 · Cited by 6
Increasing the COVID‐19 immunization rate through allergy testing
Bent, R. K., Weinbrenner, J., Faihs, V., Steffens, S., Nau, T., Vitus, M. V., Mathes, S., Darsow, U. G., Biedermann, T., & Brockow, K. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18979 · Cited by 6
Anaphylactic reactions after COVID-19 vaccination in Germany
Barth, I., Weißer, K., Gaston-Tischberger, D., Mahler, V., & Keller‐Stanislawski, B. (2023) · Allergologie select · doi:10.5414/alx02374e · Cited by 6
Kampo Medicine Treatment for Coronavirus Disease 2019 (COVID-19)
Takayama, S., Namiki, T., Odaguchi, H., Mitani, K., Yakubo, S., Hisanaga, A., Kainuma, M., & Takashi, I. T. O. (2022) · 日本東洋醫學雜誌 · doi:10.3937/kampomed.73.117 · Cited by 6
A randomized double-blinded trial to assess recurrence of systemic allergic reactions following COVID-19 mRNA vaccination
Khalid, M. B., Zektser, E., Chu, E., Li, M., Utoh, J., Ryan, P. B., Loving, H. S., Harb, R., Kattappuram, R., Chatman, L., et al. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.03.001 · Cited by 6
Propensity-Score-Matched Evaluation of Adverse Events Affecting Recovery after COVID-19 Vaccination: On Adenovirus and mRNA Vaccines
Son, C.-S., Jin, S. H., & Kang, W. (2022) · Vaccines · doi:10.3390/vaccines10020284 · Cited by 6
COVID‐19 vaccination in children and adolescents aged 5 years and older undergoing treatment for cancer and non‐malignant haematological conditions: Australian and New Zealand Children’s Haematology/Oncology Group consensus statement
Furlong, E., Kotecha, R. S., Conyers, R. K., O'Brien, T. A., Hansford, J. R., Super, L., Downie, P., Eisenstat, D. D., Haeusler, G. M., McMullan, B. J., et al. (2022) · The Medical Journal of Australia · doi:10.5694/mja2.51444 · Cited by 5
Disproportionality analysis of anaphylactic reactions after vaccination with messenger RNA coronavirus disease 2019 vaccines in the United States
Nava, G. R., Egoryan, G., Trelles-Garcia, D. P., Yanez‐Bello, M. A., & Murguia-Fuentes, R. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.04.004 · Cited by 6
COVID-19 vaccination including 198 patients with history of severe anaphylactic reaction – own observations
Wentrys, Ł., & Stopyra, L. (2022) · Przeglad Epidemiologiczny · doi:10.32394/pe.75.28 · Cited by 6
Between COVID-19 severity and its prevention – what should rheumatologists be aware of?
Makowska, J. S., & Styrzyński, F. (2021) · Reumatologia/Rheumatology · doi:10.5114/reum.2021.103941 · Cited by 6
The Application of Single-Cell Technologies for Vaccine Development Against Viral Infections
Nguyen, H. N., Vanderzee, I., & Wen, F. (2025) · Vaccines · doi:10.3390/vaccines13070687 · Cited by 7
Immediate reactions after mRNA SARS-CoV-2 vaccination
Jeimy, S. B., Wong, T. H., & Song, C. (2021) · Canadian Medical Association Journal · doi:10.1503/cmaj.211581 · Cited by 5
Hypersensitivity reactions to vaccines in children: from measles to SARS‐CoV‐2
Caffarelli, C., Liotti, L., Bianchi, A., Bottau, P., Caimmi, S. M. E., Crisafulli, G., Franceschini, F., Paglialunga, C., Saretta, F., & Mori, F. (2022) · Pediatric Allergy and Immunology · doi:10.1111/pai.13631 · Cited by 5
Hypertensive Anaphylaxis After Moderna COVID-19 Vaccination: A Case Report
Furuto, Y., Nohara, T., Hamada, H., & Shibuya, Y. (2022) · Cureus · doi:10.7759/cureus.25586 · Cited by 5
Psychological and Psychiatric Events Following Immunization with Five Different Vaccines against SARS-CoV-2
García-Alanis, M., Morales-Cárdenas, M., Toapanta-Yanchapaxi, L. N., Chiquete, E., Núñez, I., Ceballos‐Liceaga, S. E., Carbajal‐Sandoval, G., Toledo‐Salinas, C., Mendoza-Hernández, D. A., Scheffler‐Mendoza, S., et al. (2022) · Vaccines · doi:10.3390/vaccines10081297 · Cited by 5
Incidence Rates and Clinical Characteristics of Patients With Confirmed Myocarditis or Pericarditis Following COVID-19 mRNA Vaccination: Experience of the Veterans Health Administration Through 9 October 2022
Luo, J., Hur, K., Salone, C., Huang, N., Burk, M. L., Pandey, L., Thakkar, B., Donahue, M., & Cunningham, F. E. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad268 · Cited by 5
Safety monitoring of COVID-19 vaccines: February 26, 2021, To June 4, 2022, Republic of Korea
Lee, Y.-K., Kwon, Y., Heo, Y., Kim, E. K., 김, 승., Cho, H.-J., Kim, S., Ko, M., Lim, D., Seo, S.-Y., et al. (2023) · Korean Journal of Pediatrics · doi:10.3345/cep.2022.00815 · Cited by 5
Polysorbate 80-containing ionizable lipid nanoparticles for mRNA delivery
Tang, X., Ding, S., Yang, S., Cheng, Y., Liu, H., Chen, K., & Han, X. (2024) · Biomaterials Science · doi:10.1039/d4bm00523f · Cited by 5
Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 – a review
Akamine, C. M., & Sahly, H. M. E. (2021) · Translational research · doi:10.1016/j.trsl.2021.12.007 · Cited by 5
Patients with previous immediate hypersensitivity reactions to polyethylene glycol can safely receive the BNT162b2 mRNA COVID‐19 vaccine
Hurst, M., Jordan, A., Capstick, J., Brewerton, M., Cockroft, R., & Ingram, J. G. (2022) · Internal Medicine Journal · doi:10.1111/imj.15821 · Cited by 5
Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis With Periaortitis That Developed After mRNA COVID-19 Vaccination
Yoshino, Y., & Ishida, T. (2023) · Cureus · doi:10.7759/cureus.37480 · Cited by 5
Oral adverse events following COVID-19 and influenza vaccination in Australia
Riad, A., Issa, J., Attia, S., Dušek, L., & Klugar, M. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2253589 · Cited by 5
Adverse reactions to mRNA coronavirus disease 2019 (COVID-19) vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 576 medical staff.
Hayashi, M., Morikawa, S., Goto, Y., Yoshida, T., Kimura, Y., & Imaizumi, K. (2022) · PubMed Central · doi:10.20407/fmj.2021-009 · Cited by 5
Cohort monitoring of 29 Adverse Events of Special Interest prior to and after COVID-19 vaccination in four large European electronic healthcare data sourcesPreprint
Sturkenboom, M., Messina, D., Paoletti, O., de Burgos‐Gonzalez, A., García-Poza, P., Huerta, C., Llorente‐García, A., Martín‐Pérez, M., Martínez, M. T., Martin, I., et al. (2022) · medRxiv · doi:10.1101/2022.08.17.22278894 · Cited by 4
Preliminary Report of Nationwide COVID-19 Vaccine Compensation in Taiwan
Lu, Y., Huang, C., Chi, H., Lin, C., & Chiu, N. (2024) · Healthcare · doi:10.3390/healthcare12131250 · Cited by 4
National Pharmacovigilance Assessment of Oral Adverse Events Following COVID-19 Vaccination in Germany (2020-2023)
Riad, A. (2025) · International Dental Journal · doi:10.1016/j.identj.2025.100906 · Cited by 4
Detection of PEG-specific antibodies in SARS-CoV-2 positive and negative sera with implications for autoimmune reactivity
Vojdani, A., & Vojdani, E. (2025) · Scientific Reports · doi:10.1038/s41598-025-17777-6 · Cited by 3
Allergological study in patients vaccinated against COVID-19 with suspected allergic reactions
Cerdá, V. J., Pacheco, R. R., Witek, J. D., Hernández, S. A., Garcı́a, R. D., Panisello, M. R., & de la Calle, F. M. M. (2022) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-022-00685-z · Cited by 4
Risk of Adverse Events of Live-Attenuated COVID-19 Vaccination Among Atopic Patients
Chiewchalermsri, C., Hengkrawit, K., Srinithiwat, P., Kiatsermkachorn, W., & Luecha, O. (2022) · Journal of Asthma and Allergy · doi:10.2147/jaa.s386611 · Cited by 4
Management of coronavirus disease 2019 vaccine-induced cutaneous complications: A comprehensive literature review
Rubaian, N. F. B., Aljalfan, A. A. N., & Almuhaidib, S. R. (2023) · Journal of Family and Community Medicine · doi:10.4103/jfcm.jfcm_3_23 · Cited by 3
The effects of the Covid-19 vaccine on menstrual disorders in women of reproductive age
Yoosefian, M., Esmaeili, A., Parizi, Z. P., Kermanshahaninezhad, S. O., & Babaki, B. S. (2023) · Journal of Public Health · doi:10.1007/s10389-023-02120-y · Cited by 4
COVID-19 Vaccination in Patients With Inflammatory Bowel Disease and History of Reaction to Injectable Therapies
Squire, J. D., Gonzalez‐Estrada, A., Caldera, F., & Farraye, F. A. (2021) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izab094 · Cited by 4
Delayed local reactions after the first administration of the ChAdOx1 nCoV‐19 vaccine
Shin, E., Bae, S., Jung, J., Song, W., Kwon, H., Kim, H., Kim, S., Kim, T., Cho, Y. S., & Lee, J. (2021) · Allergy · doi:10.1111/all.14978 · Cited by 4
Potential prophylactic efficacy of mast cell stabilizers against COVID-19 vaccine-induced anaphylaxis
Kazama, I. (2021) · Clinical and Molecular Allergy · doi:10.1186/s12948-021-00162-9 · Cited by 4
Elucidating Pathways Mediating the Relationship Between Male Sex and COVID-19 Severity
Stalter, R. M., Atluri, V., Xia, F., Thomas, K. K., Lan, K. F., Greninger, A. L., & Patel, R. C. (2022) · Clinical Epidemiology · doi:10.2147/clep.s335494 · Cited by 4
Guillain-Barre Syndrome After COVID-19 Vaccination: A Secondary Analysis of Domestic Safety Data by the Japanese Government
Kaneda, Y., Hashimoto, T., Kaneda, U., Higuchi, Y., Murakami, J., Inada, M., Senoo, Y., Fujieda, T., Murata, Y., & Tanimoto, T. E. (2022) · Cureus · doi:10.7759/cureus.30905 · Cited by 4
The usability of testing skin reaction applying skin prick tests with Comirnaty (Pfizer, USA) vaccine in detecting the risk of developing post-vaccination immediate hypersensitivity response (anaphylaxis) after administration of this vaccine
Gulas, E., Bant, A., Kruszewski, J., Betiuk, B., Niedoszytko, M., & Chciałowski, A. (2023) · Advances in Dermatology and Allergology · doi:10.5114/ada.2023.131860 · Cited by 4
COVID-19 vaccines and blood glucose control: Friend or foe?
Vena, W., Pigni, S., Betella, N., Navarra, A., Mirani, M., Mazziotti, G., Lania, A. G., & Bossi, A. C. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2363068 · Cited by 4
EXOGENOUS Sex Hormones and Sex Hormone Receptor Modulators in COVID‐19: Rationale and Clinical Pharmacology Considerations
Zou, P., Heath, A., Sewell, C. A., Lu, Y., Tran, D. C., & Seo, S. K. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2508 · Cited by 4
Safety and efficacy of graded dosing of Pfizer-BioNTech mRNA COVID-19 vaccine after an immediate hypersensitivity reaction to first dose
Regula, P., Rosenstreich, D. L., Jerschow, E., Ramesh, M., Ferastraoaru, D. E., Oh, J., Aivazi, D. S., Aivazi, J. M., & Hudes, G. (2022) · Journal of Allergy and Clinical Immunology Global · doi:10.1016/j.jacig.2022.04.005 · Cited by 4
Preparing the Allergist/Immunologist for the Next Pandemic
Williams, P. V., Fasano, M. B., & Fleisher, T. A. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.07.037 · Cited by 4
Safety of an inactivated COVID-19 vaccine in patients with - wheat-dependent exercise-induced anaphylaxis
Du, Z., & Yin, J. (2022) · Allergologia et Immunopathologia · doi:10.15586/aei.v50i3.570 · Cited by 4
Immune parameters during anaphylaxis to messenger RNA coronavirus disease 2019 vaccines
de Chaisemartin, L., Diep, A., Gonnin, C., Soria, A., Barbaud, A. M., & Nicaise‐Roland, P. (2022) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.11.012 · Cited by 5
Post-emergency use authorization active safety surveillance study of the Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine in the Veterans Affairs health system: Findings from a three-year, comprehensive safety assessment program
Asomaning, K., Duh, M. S., DerSarkissian, M., de Luise, C., Nguyen, C., Cheng, M., Lax, A., Guo, T., Cunnington, M. C., Crémieux, P., et al. (2026) · Vaccine X · doi:10.1016/j.jvacx.2026.100791 · Cited by 3
Allergie und COVID‐19 – Daten statt Polemik
Wöhrl, S. (2021) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14519_g · Cited by 3
Subjektives Wohlbefinden und Arbeitsfähigkeit von Krankenhauspersonal nach SARS-CoV-2-Immunisierung mit dem mRNS-Impfstoff BNT162b2 – Ergebnisse einer anonymen Umfrage
Kalbhenn, J., Hammer, T., Hug, M., Dürschmied, D., Wenz, F. K., & Steinmann, D. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1520-2127 · Cited by 3
A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine
Pather, S., Charpentier, N., van den Ouweland, F., Rizzi, R., Finlayson, A., Salisch, N. C., Muik, A., Lindemann, C., Khanim, R., Abdul-Jawad, S., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126165 · Cited by 3
Serious adverse events following immunization with COVID-19 vaccines in Lebanon: a retrospective analysis of the National Pharmacovigilance Database
Karam, R., Iskandar, K., Watfa, M., & Zeitoun, A. (2024) · BMC Public Health · doi:10.1186/s12889-024-20297-z · Cited by 3
COVID-19 and Myocarditis: Pathogenetic Mechanisms and Histological Features
Salzillo, C., & Marzullo, A. (2025) · Acta Microbiologica Hellenica · doi:10.3390/amh70010003 · Cited by 4
The Future of mRNA Vaccines: Potential Beyond COVID-19
Saxena, S., Mandrah, V., Tariq, W., Das, P., Sambhav, K., & Devi, S. H. (2025) · Cureus · doi:10.7759/cureus.84529 · Cited by 8
Evaluation of anaphylaxis risk by skin testing with coronavirus disease 2019 messenger RNA vaccines on patients with anaphylaxis
Pienkowski, M. M., & Pienkowski, S. M. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.09.021 · Cited by 3
Eventos adversos em unidades de saúde do estado da Bahia, antes e durante a COVID-19
Oliveira, L. G. F., Boere, V., & Silva, I. D. O. E. (2022) · Revista Recien · doi:10.24276/rrecien2022.12.37.206-210 · Cited by 3
Immunization for midlife women
Brown, V. (2022) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002024 · Cited by 3
Allergy Workup in the Diagnosis of COVID-19 Vaccines-Induced Hypersensitivity Reactions and Its Impact on Vaccination
Petrelli, F., Giannini, D., Pucci, C., Corso, I. D., Rocchi, V., Dolcher, M. P., Pieve, G., Pratesi, F., Migliorini, P., & Puxeddu, I. (2022) · International Archives of Allergy and Immunology · doi:10.1159/000526764 · Cited by 3
Case mistaken for leukemia after mRNA COVID-19 vaccine administration: A case report
Lee, S. B., Park, C. Y., Park, S.-G., & Lee, H. J. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i33.12268 · Cited by 3
Adverse event reports of anaphylaxis after Comirnaty and Vaxzevria COVID‐19 vaccinations, Western Australia, 22 February to 30 June 2021
Shivarev, A., Phillips, A., Brophy‐Williams, S., Ford, T., Richmond, P., Effler, P. V., & McLean‐Tooke, A. P. (2022) · Internal Medicine Journal · doi:10.1111/imj.16001 · Cited by 3
Effects of gender on the efficacy and response to COVID-19 vaccination; a review study on current knowledge
Rastegar-Kashkouli, A., Jafari, M., & Yousefi, P. (2022) · Journal of Renal Endocrinology · doi:10.34172/jre.2022.25064 · Cited by 3
Side effects after COVID-19 vaccination: a comparison between the most common available vaccines in Iran
Yadegarynia, D., Tehrani, S., Hadavand, F., Arshi, S., Abtahian, Z., Keyvanfar, A., Darvishi, A., Zarghi, A., Gachkar, L., Darazam, I. A., et al. (2023) · Iranian Journal of Microbiology · doi:10.18502/ijm.v15i2.12467 · Cited by 3
Analysis of Allergy and Hypersensitivity Reactions to COVID-19 Vaccines According to the EudraVigilance Database
Romantowski, J., Nazar, W., Bojahr, K., Popiołek, I., & Niedoszytko, M. (2024) · Life · doi:10.3390/life14060715 · Cited by 2
Adverse reactions to BNT162B2 vaccine in health care workers from an Italian Tertiary Care Hospital
Guarnieri, V., Barni, S., Giovannini, M., Liccioli, G., Sarti, L., Ricci, S., Lodi, L., Canessa, C., Lippi, F., Moriondo, M., et al. (2022) · Clinical & Experimental Allergy · doi:10.1111/cea.14155 · Cited by 3
COVID-19 vaccine concerns of health care providers and ancillary staff
Lewin, B. J., Bronstein, D. E., Tubert, J. E., Chang, J. M., Luo, Y., Choi, K. R., Munoz‐Plaza, C. E., Rondinelli, J. L., & Bruxvoort, K. J. (2022) · Pediatric Research · doi:10.1038/s41390-022-02171-z · Cited by 3
Restrictions on Movement
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.003.0004 · Cited by 3

Authors: Shimabukuro, T. T., Cole, M., & Su, J. R.
Affiliations: Centers for Disease Control and Prevention (US)
ORCID: Shimabukuro, Tom T.
Su, John R.
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 2021-03-16
Volume: 325
Issue: 11
Pages: 1101
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.2021.1967
PMC: PMC8890485
OpenAlex: W3128551684
Cited by: 475
References: 8
Citations by year: 2026: 22 · 2025: 27 · 2024: 30 · 2023: 104 · 2022: 136 · 2021: 156
FWCI: 33.73
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: JAMA (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (CC999999)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
Keywords: anaphylaxis, COVID-19 mRNA vaccine, BNT162b2, Moderna vaccine, vaccine adverse events, vaccine safety
MeSH terms: COVID-19 Vaccines, Adult, Anaphylaxis, Female, Hospitalization, Humans, Male, Middle Aged, United States, Adverse Drug Reaction Reporting Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks